Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes - Scorecard - MDSpire
Advertisement
Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes
Clinical Scorecard: Variable Outcomes of Early Initiation of Sacubitril/Valsartan Following PCI in Older Adults with Left Ventricular Dysfunction: Impact on Myocardial Recovery and Mid-Term Cardiovascular Results
At a Glance
Category
Detail
Condition
Key Mechanisms
Sacubitril/valsartan as an angiotensin receptor–neprilysin inhibitor (ARNI) improving myocardial recovery.
Target Population
Care Setting
Key Highlights
Early initiation of sacubitril/valsartan (≤7 days) was associated with improved left ventricular ejection fraction and cardiac index at 8 weeks.
The early initiation group had a lower incidence of major adverse cardiovascular events (MACE) at 12 months (8.3%) compared to delayed (20.8%) and control (25.0%) groups.
Early initiation was associated with greater reductions in inflammatory and cardiac injury biomarkers, including hs-CRP and NT-proBNP.
Guideline-Based Recommendations
Diagnosis
Management
Consider early initiation of sacubitril/valsartan within 7 days post-PCI for eligible patients.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The study suggests early initiation of sacubitril/valsartan may enhance myocardial recovery and reduce cardiovascular risk.
Clinical Best Practices
Implement early pharmacological strategies post-PCI in elderly patients with left ventricular dysfunction.
Utilize echocardiographic and biomarker assessments to guide treatment efficacy.
